Target organ expression and biomarker characterization of chemokine CCL21 in systemic sclerosis associated pulmonary arterial hypertension

By sjmartinez • October 11, 2022

Didriksen H, Molberg Ø, Mehta A, Jordan S, Palchevskiy V, Fretheim H, Gude E, Ueland T, Brunborg C, Garen T, Midtvedt Ø, Andreassen AK, Lund-Johansen F, Distler O, Belperio J, Hoffmann-Vold AM. Target organ expression and biomarker characterization of chemokine CCL21 in systemic sclerosis associated pulmonary arterial hypertension. Front Immunol. 2022 Sep 23;13:991743. doi: 10.3389/fimmu.2022.991743. PMID: 36211384; PMCID: PMC9541617.

Tags: Anti-CCL21, CCL21, ELISA Enzyme-linked immunosorbent assay, Luminex (xMAP) method, Publications, pulmonary arteria hypertension, Pulmonary, Critical Care & Sleep Medicine, systemic sclerosis

Author Correction: Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia

Koeberl D, Schulze A, Sondheimer N, Lipshutz GS, Geberhiwot T, Li L, Saini R, Luo J, Sikirica V, Jin L, Liang M, Leuchars M, Grunewald[...]

Diet and the gut microbiome in patients with Parkinson’s disease

Kwon D, Zhang K, Paul KC, Folle AD, Del Rosario I, Jacobs JP, Keener AM, Bronstein JM, Ritz B. Diet and the gut microbiome in[...]

Treatment for Rheumatoid Arthritis Associated With Alterations in the Gastrointestinal Microbiota

Andréasson K, Olofsson T, Lagishetty V, Alrawi Z, Klaassens E, Holster S, Hesselstrand R, Jacobs JP, Wallman JK, Volkmann ER. Treatment for Rheumatoid Arthritis Associated[...]